Abstract
Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have